Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWS): A preliminary report.

Sergio Bracarda,Giuseppe Procopio,Daniele Alesini,Francesco Grillone,Francesco Massari,Alberto Zaniboni,Rodolfo Mattioli,S. Buti,Enrico Garanzini,Michele Sisani,Alketa Hamzaj,Amelia Altavilla,Verena De Angelis

Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWS): A preliminary report.

2014

Sergio Bracarda
Giuseppe Procopio
Daniele Alesini
Francesco Grillone
Francesco Massari
Alberto Zaniboni
Rodolfo Mattioli
S. Buti
Enrico Garanzini
Michele Sisani
Alketa Hamzaj
Amelia Altavilla
Verena De Angelis

e16058 Background: AWS is defined as decline in PSA after withdrawal of an antiandrogen (AA) during maximum androgen blockade and it has been described in less than 20% of mCRPC patients. The most ...

Keywords:

Antiandrogen
Withdrawal syndrome
Prostate cancer
Castration
Enzalutamide
Physical therapy
Cancer research
Medicine
castration resistant
preliminary report
Oncology
Internal medicine
in patient
Maximum androgen blockade
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations